In short
This article discusses a clinical trial investigating the use of very potent corticosteroids (Group IV) in combination with a new drug called lebrikizumab for treating moderate-to-severe atopic dermatitis in children and teenagers. The study aims to assess the effectiveness and safety of this combination therapy compared to a placebo in young patients aged 6 months to under 18 years.
At a glance
- Study Type
- Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
- Main Objective
- Evaluate efficacy of lebrikizumab with topical corticosteroids vs. placebo
- Participant Age Range
- 6 months to <18 years
- Condition Studied
- Moderate-to-Severe Atopic Dermatitis
- Corticosteroid Type
- Very Potent (Group IV), Topical Application
- Primary Endpoints
- IGA score improvement, EASI-75 achievement
- Treatment Duration
- Up to 18 weeks
- Key Inclusion Criteria
- Atopic dermatitis duration, age and weight requirements
- Key Exclusion Criteria
- Recent similar studies, pregnancy, severe infections, drug reactions
What are Corticosteroids, Very Potent (Group IV)?
Corticosteroids, Very Potent (Group IV) are a type of medication used to treat various skin conditions. They belong to the strongest group of topical corticosteroids available and are typically used when other, less potent corticosteroids have not been effective.
These medications work by reducing inflammation, itching, and redness in the skin. They are synthetic versions of hormones that your body naturally produces in the adrenal glands.
Medical Conditions Treated
According to the clinical trial information, Corticosteroids, Very Potent (Group IV) are being studied for the treatment of Atopic Dermatitis, also known as Eczema.
Atopic Dermatitis is a chronic skin condition characterized by: Dry, itchy skin Redness and inflammation Recurring rash Skin thickening (in chronic cases)
How are They Administered?
The clinical trial data indicates that Corticosteroids, Very Potent (Group IV) are administered topically. This means they are applied directly to the skin, usually in the form of creams, ointments, or lotions.
Current Clinical Trial Information
A clinical trial (study number 2022-501476-25-00) is currently being conducted to assess the efficacy and safety of a drug called lebrikizumab when used in combination with topical corticosteroids for treating moderate-to-severe atopic dermatitis in children and adolescents.
The main objective of this trial is to evaluate how well lebrikizumab works when used together with topical corticosteroid treatment, compared to a placebo, in participants with moderate-to-severe atopic dermatitis.
Eligibility Criteria for the Clinical Trial
To participate in this clinical trial, patients must meet certain criteria. Some key inclusion criteria are:
- Have had Atopic Dermatitis for at least 6 months if younger than 6 years old, or 1 year if older than 6 years
- Be between 6 months and 18 years old
- Weigh over 6 kilograms if between 6 months and 6 years old
- Weigh less than 40 kilograms if between 12 and 18 years old
- Have a parent or legal guardian able to provide consent and follow study guidelines
Some exclusion criteria include:
- Recent participation in a similar study or use of certain forbidden treatments
- Pregnancy or breastfeeding
- Previous adverse reactions to the study drug or topical treatments
- Severe or current infections requiring strong antibiotics
- Certain medical conditions that could affect patient safety
- Drug or alcohol addiction
It's important to note that these are just some of the criteria, and a healthcare professional would need to assess full eligibility.
Dosage and Treatment Duration
According to the clinical trial information: The maximum daily dose amount is 1 (unit not specified) The maximum total dose amount is 126 (unit not specified) The maximum treatment period is 18 weeks It's important to note that these dosages are specific to the clinical trial and may not reflect standard treatment regimens. Always follow your doctor's instructions regarding dosage and treatment duration.
Precautions and Considerations
When using Corticosteroids, Very Potent (Group IV), it's important to be aware of the following: Potency: These are the strongest topical corticosteroids available. They should be used only as prescribed and for the shortest duration necessary. Side effects: Prolonged use can lead to skin thinning, stretch marks, or other skin changes. Always inform your doctor of any side effects. Application: Follow your healthcare provider's instructions carefully on how and where to apply the medication. Monitoring: Regular check-ups may be necessary to monitor the effectiveness of the treatment and any potential side effects. Interactions: Inform your doctor about all medications you're taking, as there may be interactions with other drugs. Always consult with your healthcare provider for personalized advice and information about using Corticosteroids, Very Potent (Group IV).